BridgeBio raises $1B via preferred equity from Sixth Street and KKR's HealthCare Royalty, stockpiling cash ahead of three drug launches within 18 months.
July 1, 2026 10:29 AM EDT
Financing
BridgeBio adds $1B as it prepares three more drug launches
Kyle LaHucik
Biotech Correspondent
Things are happening fast at BridgeBio as it plugs away at the launch of blockbuster-in-waiting Attruby and prepares to…
Nonprofit Blood Cancer United acquires cancer drug, Lilly and Nvidia invest in Abridge, and more biotech news
Biogen pays up to $1B for secretive San Diego biotech RayThera, gaining three undisclosed anti-inflammatory candidates to expand…
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and…
BridgeBio attracts $1B in equity for new launches, but analyst smells M&A ‘dry powder’
More signs that GLP-1s may help with peripheral artery disease
Beeline ups its Series A round for immune drug work
Metis TechBio seals $1.62b global licensing deal with Boulevard Bio
Zymeworks acquires struggling Theravance for $929M
